FR2713087B1 (en)* | 1993-11-30 | 1996-02-23 | Saurat Jean Hilaire | Use of selegiline and its derivatives for the preparation of a medicament intended for the treatment of psoriasis. |
US6319954B1 (en)* | 1995-01-13 | 2001-11-20 | Somerset Pharmaceuticals, Inc. | S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions |
US6299901B1 (en) | 1995-01-13 | 2001-10-09 | Somerset Pharmaceuticals, Inc. | Methods and pharmaceutical compositions employing desmethylselegiline |
CA2212412A1 (en)* | 1995-02-10 | 1996-08-15 | The University Of Toronto Innovations Foundation | Deprenyl compounds for treatment of glaucoma |
JPH11506744A (en) | 1995-06-07 | 1999-06-15 | ノウブン ファーマシューティカルズ インク. | Transdermal compositions containing low molecular weight drugs that are liquid at room temperature |
US6316022B1 (en) | 1995-06-07 | 2001-11-13 | Noven Pharmaceuticals, Inc. | Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures |
DE19746191C2 (en)* | 1997-10-18 | 2000-05-18 | Lohmann Therapie Syst Lts | Method of using an active ingredient-containing patch to combat or alleviate addiction |
US6210705B1 (en)* | 1997-12-15 | 2001-04-03 | Noven Pharmaceuticals, Nc. | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
US7083808B2 (en) | 1998-12-17 | 2006-08-01 | Euro-Celtique S.A. | Controlled/modified release oral methylphenidate formulations |
US6419960B1 (en) | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
US6673367B1 (en) | 1998-12-17 | 2004-01-06 | Euro-Celtique, S.A. | Controlled/modified release oral methylphenidate formulations |
US6280763B1 (en) | 1999-05-10 | 2001-08-28 | Pierce Management, Llc | Apparatus and method for transdermal delivery of bupropion |
WO2003039525A1 (en) | 2001-11-05 | 2003-05-15 | Krele Pharmaceuticals Llc | Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism |
IL165249A0 (en) | 2002-07-18 | 2005-12-18 | Cytos Biotechnology Ag | Hapten-carrier conjugates and uses thereof |
US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
EP1686973A4 (en) | 2003-11-25 | 2009-03-25 | Technion Res & Dev Foundation | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISORDERS AND DISEASES |
US8263655B2 (en) | 2005-10-06 | 2012-09-11 | Technion Research And Development Foundation Ltd | Methods for treatment of renal failure |
DE102006038719A1 (en) | 2006-08-18 | 2008-02-21 | Tesa Ag | Pressure-sensitive adhesive strips for moisture-resistant, removable adhesive bonds |
US8278345B2 (en) | 2006-11-09 | 2012-10-02 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
CN101668525A (en) | 2007-03-01 | 2010-03-10 | 前体生物药物股份公司 | New use of glutaminyl cyclase inhibitors |
EP2142514B1 (en) | 2007-04-18 | 2014-12-24 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
BR112012008346B1 (en) | 2009-09-11 | 2021-12-21 | Vivoryon Therapeutics N.V. | HETEROCYCLIC DERIVATIVES, THEIR PREPARATION PROCESS, AND PHARMACEUTICAL COMPOSITION |
US9943489B2 (en) | 2010-02-03 | 2018-04-17 | Pharmatwob Ltd. | Extended release formulations of rasagiline and uses thereof |
EP2542549B1 (en) | 2010-03-03 | 2016-05-11 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
KR101790806B1 (en) | 2010-03-10 | 2017-11-20 | 프로비오드룩 아게 | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
JP6355921B2 (en) | 2010-09-01 | 2018-07-11 | トニックス ファーマスーティカルズ, インコーポレイテッドTONIX Pharmaceuticals, Inc. | Treatment of addiction to cocaine |
ES2570167T3 (en) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Benzimidazole derivatives as glutaminyl cyclase inhibitors |
US9937144B2 (en) | 2013-01-30 | 2018-04-10 | The Johns Hopkins University | Treatment of drug abuse by preventing GAPDH nitrosylation |
CA3018328A1 (en) | 2014-10-31 | 2016-04-30 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
EP3461819B1 (en) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |